Hematology 2021: MDS/MPN

CME

Key Studies in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Independent Conference Coverage of the 2021 ASH Annual Meeting

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: May 11, 2022

Expiration: May 10, 2023

Amy E. DeZern
Amy E. DeZern, MD, MHS
Srdan Verstovsek
Srdan Verstovsek, MD, PhD

Activity

Progress
1
Course Completed

In this activity, Srdan Verstovsek, MD, PhD, reviews key studies in myeloproliferative neoplasms (MPN), presented at the 2021 American Society of Hematology (ASH) Annual Meeting, focusing on new data improving the treatment of patients with myeloid/lymphoid neoplasm with fibroblast growth factor receptor 1 rearrangement (MLNFGFR1), polycythemia vera (PV), and myelofibrosis (MF). Amy E. DeZern, MD, MHS, will review key data from ASH 2021 in myelodysplastic syndromes (MDS), focusing on improved prognostic assessment and emerging therapeutic strategies for patients with low-risk and high-risk disease.

Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets that also can be found here, each focused on the specific study or topic of interest. These slidesets also may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with MDS or MPN do you provide care for in a typical month?

Which of the following would you discuss as a promising investigational therapy for a patient diagnosed with a myeloid neoplasm with an FGFR1 rearrangement, based on data from the FIGHT-203 trial presented at the ASH 2021 annual meeting?

Which of the following regimens has shown preliminary activity as induction therapy in patients with high-risk MDS that may help bridge patients to allogeneic stem cell transplantation?

Which of the following findings was reported by Brunner and colleagues in a multiarm, open-label phase Ib trial that evaluated the combination of sabatolimab, a novel TIM3 inhibitor, plus HMA among patients with very high-risk and high-risk MDS who were unfit or ineligible for standard chemotherapy and who had not received previous HMA therapy?